Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers

Background : Mesalazine (5‐aminosalicylic acid)‐containing formulations, designed to optimize drug delivery to the ileo‐caecal region, represent a cornerstone in the treatment of inflammatory bowel diseases.

[1]  P. Gionchetti,et al.  Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease , 2005, Digestive Diseases and Sciences.

[2]  I. Wilding,et al.  Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation , 1992, Pharmaceutical Research.

[3]  R. M. Franz,et al.  Correlation of Ibuprofen Bioavailability with Gastrointestinal Transit by Scintigraphic Monitoring of 171Er-Labeled Sustained-Release Tablets , 1987, Pharmaceutical Research.

[4]  I. Wilding,et al.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms , 2004, European Journal of Nuclear Medicine.

[5]  J. Mate,et al.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. , 2002, Digestive diseases and sciences.

[6]  U. Klotz.  The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease , 2000, European Journal of Clinical Pharmacology.

[7]  M. Stolte,et al.  Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis , 2000 .

[8]  M. De Vos.  Clinical pharmacokinetics of slow release mesalazine. , 2000, Clinical pharmacokinetics.

[9]  D. Fleisher,et al.  Intestinal metabolism and transport of 5-aminosalicylate. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[10]  U. Klotz,et al.  Delivery and fate of oral mesalamine microgranules within the human small intestine. , 1995, Gastroenterology.

[11]  I. Wilding,et al.  Localization of Drug Release Sites from an Oral Sustained‐Release Formulation of 5‐ASA (Pentasa®) in the Gastrointestinal Tract Using Gamma Scintigraphy , 1993, Journal of clinical pharmacology.

[12]  U. Klotz,et al.  Oroileal transit of slow release 5-aminosalicylic acid. , 1993, Gut.

[13]  S. Hanauer,et al.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.

[14]  R. Modigliani,et al.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) , 1993, Gastroenterology.

[15]  I. Wilding,et al.  Scintigraphic and pharmacokinetic assessment of a multiparticulate sustained release formulation of diltiazem , 1991 .

[16]  D. Evans,et al.  Evaluation of an enteric‐coated naproxen pellet formulation , 1991, Alimentary pharmacology & therapeutics.

[17]  J. Rask-Madsen,et al.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. , 1990, Gut.

[18]  A. Parr,et al.  Gastrointestinal Behavior of Orally Administered Radiolabeled Erythromycin Pellets in Man as Determined by Gamma Scintigraphy , 1990, Journal of clinical pharmacology.

[19]  J. Hardy,et al.  Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease , 1987, Alimentary pharmacology & therapeutics.

[20]  J. Hardy,et al.  Gastrointestinal transit of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet , 1987, Alimentary pharmacology & therapeutics.

[21]  E. Brendel,et al.  Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography. , 1987, Journal of chromatography.

[22]  B. Krevsky,et al.  Colonic transit scintigraphy. A physiologic approach to the quantitative measurement of colonic transit in humans. , 1986, Gastroenterology.

[23]  S. Bondesen,et al.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man. , 1983, British journal of clinical pharmacology.

[24]  U. Klotz,et al.  Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. , 1981, Journal of chromatography.

[25]  M. Peppercorn,et al.  Distribution studies of salicylazosulfapyridine and its metabolites. , 1973, Gastroenterology.

[26]  H. Schröder,et al.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man , 1972, Clinical pharmacology and therapeutics.